Sensitive content

This media may contain sensitive content.

Loading video...

Video Failed to Load

There was a problem loading this video. This could be due to a temporary network issue or the video might be unavailable.

Reporting in for the initial processing procedures… Stage 1 commencing… ⛓️🔝: Nex 1068 #rubberdrone #rubberfetish #rubberkink #rubberkinkster #rubbergear #fullrubbercoverage #gearhead

Tex 🔜 GBUS

7,189 subscribers

16,953 views • 3 years ago •via X (Twitter)

NSFW #rubberdrone #rubberfetish #rubberkink #rubberkinkster #rubbergear #fullrubbercoverage #gearhead

Anya Rossi• Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

The sweet sounds of the load extraction process… All for the collective!! This is the WAY!! ⛓️🔝: Nex 1068

Sensitive content

The sweet sounds of the load extraction process… All for the collective!! This is the WAY!! ⛓️🔝: Nex 1068

Tex 🔜 GBUS

60,907 views • 3 years ago

Real Reasons why Dua Lipa Cancelled Jakarta's show. 1. The stage level is very low, unlike the ones in Singapore. Which is unsafe for Dua and her dancers & band members. People can always jumped into stage that way. 2. The space of the venue is too small with the stage in 3.Few parts of the stage are still not finished building on H-1 4. All of these faults are on the promoter, as Dua have standardized stage and safety procedures that need to be met, and the promoter clearly did not heed that part of contract. 5. These Promoter are already notorious for putting an outrageous ticket prices and bad reputation for Coldplay show in Jakarta last time out.

Real Reasons why Dua Lipa Cancelled Jakarta's show. 1. The stage level is very low, unlike the ones in Singapore. Which is unsafe for Dua and her dancers & band members. People can always jumped into stage that way. 2. The space of the venue is too small with the stage in 3.Few parts of the stage are still not finished building on H-1 4. All of these faults are on the promoter, as Dua have standardized stage and safety procedures that need to be met, and the promoter clearly did not heed that part of contract. 5. These Promoter are already notorious for putting an outrageous ticket prices and bad reputation for Coldplay show in Jakarta last time out.

Pop Panda

2,852,735 views • 1 year ago

Initial reporting for day 1 of the #polio vaccination campaign show over 86,000 children received a vaccine yesterday. I admire the courage and determination of the families, the vaccinators and the health workers involved in the campaign. We call on all parties to continue fulfilling their commitment on the humanitarian pauses, so that all children in need get the vaccine. This campaign again demonstrates that we need peace for health.

Initial reporting for day 1 of the #polio vaccination campaign show over 86,000 children received a vaccine yesterday. I admire the courage and determination of the families, the vaccinators and the health workers involved in the campaign. We call on all parties to continue fulfilling their commitment on the humanitarian pauses, so that all children in need get the vaccine. This campaign again demonstrates that we need peace for health.

Tedros Adhanom Ghebreyesus

90,438 views • 2 years ago

🚨 WOW! Democrats are furious nationwide after Texas Children's Hospital agreed to the following terms, which could be used as a "model" for other states 1. Open a FREE de-transgender transition clinic 2. Pay $10M in damages 3. REVOKE privileges of 5 doctors who implemented the transgender cult's ideas and NEVER hire them again 4. Acknowledge false statements about procedures done at the hospital 5. Train staff on compliance and whistleblower reporting 6. BAN gender transition services at ALL TX children facilities 👏🏻👏🏻 "Texas Attorney General Ken Paxton said the settlement is a resounding defeat for the radical gender ideology."

🚨 WOW! Democrats are furious nationwide after Texas Children's Hospital agreed to the following terms, which could be used as a "model" for other states 1. Open a FREE de-transgender transition clinic 2. Pay $10M in damages 3. REVOKE privileges of 5 doctors who implemented the transgender cult's ideas and NEVER hire them again 4. Acknowledge false statements about procedures done at the hospital 5. Train staff on compliance and whistleblower reporting 6. BAN gender transition services at ALL TX children facilities 👏🏻👏🏻 "Texas Attorney General Ken Paxton said the settlement is a resounding defeat for the radical gender ideology."

Eric Daugherty

79,720 views • 1 month ago

Vaccine Disaster: Thousands of Brits Left Disabled After COVID Shots The truth is becoming undeniable. A freedom of information request has revealed that over 14,000 people have applied for compensation through the UK's vaccine injury scheme. The claims are so widespread that “staff processing these claims had to be increased from four to 80 people last year because they were coming in so quickly.” 5 and a half thousand claims have been rejected because they were not “disabled enough,” and more than 700 people have been waiting over a year for a decision. But the devastating effects of the shots don't end there. Bev Turner reports, “By June 2021, there were already 300,000 registered adverse reactions to the UK's own yellow card reporting system. 300,000 adverse reactions. And it had always been known for decades that the yellow card reporting system is so little known about, and so poorly administered, that it only registers between one to 10% of all injuries. So that 300,000 could have been just 1% of actual adverse events.”

Vaccine Disaster: Thousands of Brits Left Disabled After COVID Shots The truth is becoming undeniable. A freedom of information request has revealed that over 14,000 people have applied for compensation through the UK's vaccine injury scheme. The claims are so widespread that “staff processing these claims had to be increased from four to 80 people last year because they were coming in so quickly.” 5 and a half thousand claims have been rejected because they were not “disabled enough,” and more than 700 people have been waiting over a year for a decision. But the devastating effects of the shots don't end there. Bev Turner reports, “By June 2021, there were already 300,000 registered adverse reactions to the UK's own yellow card reporting system. 300,000 adverse reactions. And it had always been known for decades that the yellow card reporting system is so little known about, and so poorly administered, that it only registers between one to 10% of all injuries. So that 300,000 could have been just 1% of actual adverse events.”

The Vigilant Fox 🦊

462,020 views • 2 years ago

Now we have MBC news! Both SBS&MBC reported today! 🗣It has been confirmed that an ROk army female nurse officer in her 20s is under investigation for unauthorized visit to the military base where BTS member Jin(real name is Kim Seokjin) is stationed to serve. According to a military official, a legal investigation is in progress after the division audit of the nurse officer in question was conducted. It was explained they are laser-focusing on her leaving the duty station w/o reporting. But they clarified that the legal investigation is a fact-finding stage, and thus, no specific charges will be pressed as of yet It was belatedly found that a nurse officer Lieutenant from a different army base, made an unauthorized visit to Jin’s 5th Division Training Center back in Jan. According to Article 79 of the Military Criminal Code, unauthorized absence from the duty station without reporting to superiors may lead to imprisonment or detention for up to 1 yr. Lieutenant A reportedly explained she had no idea of BTS being located at the said base, and she just went to help. Link:

Now we have MBC news! Both SBS&MBC reported today! 🗣It has been confirmed that an ROk army female nurse officer in her 20s is under investigation for unauthorized visit to the military base where BTS member Jin(real name is Kim Seokjin) is stationed to serve. According to a military official, a legal investigation is in progress after the division audit of the nurse officer in question was conducted. It was explained they are laser-focusing on her leaving the duty station w/o reporting. But they clarified that the legal investigation is a fact-finding stage, and thus, no specific charges will be pressed as of yet It was belatedly found that a nurse officer Lieutenant from a different army base, made an unauthorized visit to Jin’s 5th Division Training Center back in Jan. According to Article 79 of the Military Criminal Code, unauthorized absence from the duty station without reporting to superiors may lead to imprisonment or detention for up to 1 yr. Lieutenant A reportedly explained she had no idea of BTS being located at the said base, and she just went to help. Link:

Jiniya지니야_RunSeokjin

382,600 views • 3 years ago

This is mind-blowing, and it’s just the tip of the iceberg. NewsNation’s Rich McHugh has been on the ground in Minnesota reporting on Medicaid fraud. After his initial report in November, he received a tip to investigate assisted living facilities. The findings are staggering. MCHUGH: “Here’s what we know now. The number of people getting help in assisted-living facilities is up double the growth of other programs.” “But here’s the kicker. The rate of payment in this assisted living space is 10 to 15 times the growth in other programs.” “So we pulled the data on assisted living facilities in the Minneapolis area.” “Minneapolis has a lot—169. Saint Paul has 83.” “But Brooklyn Center, a suburb of 30,000, has 106, and Brooklyn Park, population 84,000, has 181. More than Minneapolis, a city five times its size.” “One assisted living facility puts this all into perspective. A defendant in the ‘Feeding Our Future’ scandal owns several assisted living facilities and continues to bill the state while awaiting trial.” “Gandi Mohamed was indicted for laundering $1 million in that case. His LLC owns homes around Minneapolis. Last year, those homes brought in $2.3 million from the state.”

This is mind-blowing, and it’s just the tip of the iceberg. NewsNation’s Rich McHugh has been on the ground in Minnesota reporting on Medicaid fraud. After his initial report in November, he received a tip to investigate assisted living facilities. The findings are staggering. MCHUGH: “Here’s what we know now. The number of people getting help in assisted-living facilities is up double the growth of other programs.” “But here’s the kicker. The rate of payment in this assisted living space is 10 to 15 times the growth in other programs.” “So we pulled the data on assisted living facilities in the Minneapolis area.” “Minneapolis has a lot—169. Saint Paul has 83.” “But Brooklyn Center, a suburb of 30,000, has 106, and Brooklyn Park, population 84,000, has 181. More than Minneapolis, a city five times its size.” “One assisted living facility puts this all into perspective. A defendant in the ‘Feeding Our Future’ scandal owns several assisted living facilities and continues to bill the state while awaiting trial.” “Gandi Mohamed was indicted for laundering $1 million in that case. His LLC owns homes around Minneapolis. Last year, those homes brought in $2.3 million from the state.”

Overton

79,339 views • 9 months ago

Does anyone realize that if SpaceX pulls this off, Terafab would become the largest building ever constructed by floor area? More than 100 million square feet of manufacturing space, over 5x the floor area of the current largest building on Earth. I wanted to wait before reporting because news was coming out quite rapidly after the until announcement. SpaceX and Tesla are planning to invest roughly $16.8 billion in the initial buildout in Grimes County, Texas. It will manufacture, package and test advanced logic and memory chips under one roof because their combined demand is expected to exceed 1 terawatt of compute, more than the current global supply. The buildout is already so massive that ASML, (the only supplier of the most advanced EUV lithography machines) is factoring Terafab demand into its own 2027 and 2028 capacity plans. Elon’s rough estimate is that 25% of its AI compute output will go toward Tesla Optimus and the other 75% toward AI spacecraft. ASML has to plan years in advance for the sheer amount of chipmaking capacity Elon wants for robots and ‘ai spacecraft’

Does anyone realize that if SpaceX pulls this off, Terafab would become the largest building ever constructed by floor area? More than 100 million square feet of manufacturing space, over 5x the floor area of the current largest building on Earth. I wanted to wait before reporting because news was coming out quite rapidly after the until announcement. SpaceX and Tesla are planning to invest roughly $16.8 billion in the initial buildout in Grimes County, Texas. It will manufacture, package and test advanced logic and memory chips under one roof because their combined demand is expected to exceed 1 terawatt of compute, more than the current global supply. The buildout is already so massive that ASML, (the only supplier of the most advanced EUV lithography machines) is factoring Terafab demand into its own 2027 and 2028 capacity plans. Elon’s rough estimate is that 25% of its AI compute output will go toward Tesla Optimus and the other 75% toward AI spacecraft. ASML has to plan years in advance for the sheer amount of chipmaking capacity Elon wants for robots and ‘ai spacecraft’

Chris

81,305 views • 1 month ago

PHOTON COUNTING CT is NOT a better CT It is a NEW imaging modality Photon Counting CT (PCCT) represents a transformative leap in medical imaging, not only as a molecular imaging modality but also as a technology offering ultra-high resolution and functional imaging capabilities. It is fundamentally more than just an enhanced version of traditional CT—PCCT introduces new ways of seeing and understanding the human body, providing critical insights at the molecular, structural, and functional levels. This positions PCCT as a unique imaging modality that requires a fresh approach to technical implementation, operational workflows, and financial planning. Despite the larger upfront investment, PCCT’s ability to drastically reduce downstream healthcare costs makes it a highly valuable investment in the long run. 1. Technical Innovations • Molecular Imaging and Energy Discrimination: Unlike traditional CT, which simply measures the total absorbed energy, PCCT counts individual X-ray photons and differentiates their energy levels. This allows for precise molecular imaging, revealing the composition of tissues and materials at a biochemical level. By distinguishing between different tissue types and contrast agents, PCCT opens up new diagnostic possibilities, such as identifying molecular biomarkers in tumors or distinguishing between stable and unstable plaque in coronary arteries. This capability shifts the focus of imaging from purely anatomical to both anatomical and molecular, offering more comprehensive diagnostic information. • Ultra-High Spatial Resolution: PCCT features significantly smaller detector elements compared to conventional CT scanners, allowing for ultra-high resolution imaging. This means clinicians can visualize fine structures such as microcalcifications in arteries, small lesions in soft tissues, or the intricate architecture of bones. This level of detail was previously unattainable with traditional CT. When combined with molecular imaging, this ultra-high resolution allows for the precise localization and characterization of disease at very early stages, which is essential for early diagnosis and intervention. • Functional Imaging Capabilities: PCCT also excels as a functional imaging modality. By capturing energy-resolved information, PCCT can provide insights into tissue functionality and dynamic physiological processes. For instance, it can detect changes in blood flow, tissue perfusion, and oxygenation without the need for additional contrast agents or scans. This functionality allows for real-time assessment of physiological processes, making it particularly valuable in cardiology, oncology, and neurology for evaluating organ function and monitoring disease progression. • Reduced Noise and Artifact Reduction: Photon-counting technology dramatically reduces electronic noise and imaging artifacts, such as beam hardening, resulting in clearer and more accurate images. The ability to deliver ultra-high resolution images with minimal artifacts improves diagnostic accuracy, reducing the need for repeat scans and ensuring that even subtle abnormalities are detected. 2. Operational Considerations • New Workflow for Molecular, High-Resolution, and Functional Imaging: The integration of molecular, ultra-high resolution, and functional imaging into routine clinical workflows introduces complexity that requires adaptation. Radiologists and technicians need specialized training to interpret and analyze multi-energy datasets that include molecular and functional information. PCCT produces a vast amount of detailed data, requiring clinicians to adopt new imaging protocols and refine their diagnostic approaches to fully leverage its capabilities. • Post-Processing and Data Management: PCCT generates richer, more complex datasets, which necessitates advanced post-processing tools and data management systems. Existing PACS and imaging software may not be equipped to handle such large volumes of data or to process functional and molecular information effectively. This means healthcare institutions must invest in robust IT infrastructure, including upgraded software and storage solutions, as well as provide additional training for staff on new imaging analysis techniques. • Revised Clinical Protocols: The molecular, functional, and ultra-high resolution imaging capabilities of PCCT will likely prompt changes in clinical protocols. For instance, the need for contrast agents may be reduced, simplifying patient preparation and decreasing the risk of adverse reactions. Additionally, the ability to monitor physiological functions in real-time through functional imaging could lead to more dynamic diagnostic procedures, such as assessing the effectiveness of interventions or treatments in real-time. 3. Financial Impact • Higher Initial Investment: PCCT systems are more expensive than traditional CT scanners due to their advanced technology, which includes photon-counting detectors and the computational power required for high-resolution, molecular, and functional imaging. While this upfront cost is significant, it is crucial to view it in the broader context of the downstream benefits and cost reductions that PCCT offers. • Downstream Cost Reductions: Although the initial capital investment is higher, PCCT’s ability to combine molecular, functional, and ultra-high resolution imaging leads to substantial reductions in downstream healthcare costs. Its superior diagnostic accuracy minimizes the need for follow-up tests, repeat scans, or invasive diagnostic procedures, such as diagnostic coronary angiographies. For example, in cardiology, PCCT can precisely differentiate between types of coronary plaque, reducing the need for invasive procedures to assess risk. • Lower Overall Healthcare Expenditures: By enabling earlier, more accurate diagnoses, PCCT can reduce the overall cost of patient care. Early detection of disease, particularly through its molecular and functional imaging capabilities, allows for more targeted treatments, potentially preventing the need for more aggressive and expensive interventions down the line. For instance, early-stage tumor detection via molecular imaging could lead to less invasive treatments, reducing hospital stays and improving patient outcomes, ultimately driving down healthcare costs. • Increased ROI Through Enhanced Patient Outcomes: Over time, the combination of molecular, functional, and ultra-high resolution imaging enhances diagnostic precision, which translates into better patient outcomes. Improved diagnostic accuracy reduces the incidence of unnecessary procedures, minimizes treatment delays, and results in more personalized and effective care. This leads to increased patient satisfaction, better healthcare outcomes, and greater patient throughput—all factors that improve the institution’s return on investment (ROI). • Competitive Advantage and New Revenue Streams: By adopting PCCT, healthcare institutions position themselves at the forefront of advanced imaging technologies. The ability to offer molecular, functional, and ultra-high resolution imaging creates a competitive advantage, attracting more complex and high-value cases. This can boost the institution’s reputation for excellence in diagnostics, leading to increased referrals, new patient populations, and expanded revenue opportunities. Summary Photon Counting CT (PCCT) is not just an evolution of existing CT technology—it is a molecular, ultra-high resolution, and functional imaging modality that fundamentally transforms the diagnostic landscape. Its ability to capture detailed molecular data, visualize minute anatomical structures with ultra-high resolution, and provide real-time functional imaging opens new possibilities for earlier and more precise diagnoses. While the financial investment in PCCT is larger, the reduction in downstream healthcare costs through improved diagnostic accuracy, fewer unnecessary interventions, and earlier disease detection far outweighs the initial expense. For institutions committed to advancing patient care and improving long-term financial outcomes, PCCT is an essential investment in the future of medical imaging. The video attached shows a patient accessing the Hospital for ACS. PCCT can provide ALL the imaging information of the concurrent imaging modalities (CXR, CAG, Echo, CMR) that you see around it... that's a lot! #PhotonCountingCT #MolecularImaging #UltraHighResolution #FunctionalImaging #FutureOfImaging #AdvancedMedicalImaging #EarlyDiseaseDetection #InnovativeCT #CuttingEdgeHealthcare #PrecisionDiagnostics #HealthcareInnovation #MedicalTechnology #CostEffectiveImaging #NextGenCT #PatientCareRevolution

PHOTON COUNTING CT is NOT a better CT It is a NEW imaging modality Photon Counting CT (PCCT) represents a transformative leap in medical imaging, not only as a molecular imaging modality but also as a technology offering ultra-high resolution and functional imaging capabilities. It is fundamentally more than just an enhanced version of traditional CT—PCCT introduces new ways of seeing and understanding the human body, providing critical insights at the molecular, structural, and functional levels. This positions PCCT as a unique imaging modality that requires a fresh approach to technical implementation, operational workflows, and financial planning. Despite the larger upfront investment, PCCT’s ability to drastically reduce downstream healthcare costs makes it a highly valuable investment in the long run. 1. Technical Innovations • Molecular Imaging and Energy Discrimination: Unlike traditional CT, which simply measures the total absorbed energy, PCCT counts individual X-ray photons and differentiates their energy levels. This allows for precise molecular imaging, revealing the composition of tissues and materials at a biochemical level. By distinguishing between different tissue types and contrast agents, PCCT opens up new diagnostic possibilities, such as identifying molecular biomarkers in tumors or distinguishing between stable and unstable plaque in coronary arteries. This capability shifts the focus of imaging from purely anatomical to both anatomical and molecular, offering more comprehensive diagnostic information. • Ultra-High Spatial Resolution: PCCT features significantly smaller detector elements compared to conventional CT scanners, allowing for ultra-high resolution imaging. This means clinicians can visualize fine structures such as microcalcifications in arteries, small lesions in soft tissues, or the intricate architecture of bones. This level of detail was previously unattainable with traditional CT. When combined with molecular imaging, this ultra-high resolution allows for the precise localization and characterization of disease at very early stages, which is essential for early diagnosis and intervention. • Functional Imaging Capabilities: PCCT also excels as a functional imaging modality. By capturing energy-resolved information, PCCT can provide insights into tissue functionality and dynamic physiological processes. For instance, it can detect changes in blood flow, tissue perfusion, and oxygenation without the need for additional contrast agents or scans. This functionality allows for real-time assessment of physiological processes, making it particularly valuable in cardiology, oncology, and neurology for evaluating organ function and monitoring disease progression. • Reduced Noise and Artifact Reduction: Photon-counting technology dramatically reduces electronic noise and imaging artifacts, such as beam hardening, resulting in clearer and more accurate images. The ability to deliver ultra-high resolution images with minimal artifacts improves diagnostic accuracy, reducing the need for repeat scans and ensuring that even subtle abnormalities are detected. 2. Operational Considerations • New Workflow for Molecular, High-Resolution, and Functional Imaging: The integration of molecular, ultra-high resolution, and functional imaging into routine clinical workflows introduces complexity that requires adaptation. Radiologists and technicians need specialized training to interpret and analyze multi-energy datasets that include molecular and functional information. PCCT produces a vast amount of detailed data, requiring clinicians to adopt new imaging protocols and refine their diagnostic approaches to fully leverage its capabilities. • Post-Processing and Data Management: PCCT generates richer, more complex datasets, which necessitates advanced post-processing tools and data management systems. Existing PACS and imaging software may not be equipped to handle such large volumes of data or to process functional and molecular information effectively. This means healthcare institutions must invest in robust IT infrastructure, including upgraded software and storage solutions, as well as provide additional training for staff on new imaging analysis techniques. • Revised Clinical Protocols: The molecular, functional, and ultra-high resolution imaging capabilities of PCCT will likely prompt changes in clinical protocols. For instance, the need for contrast agents may be reduced, simplifying patient preparation and decreasing the risk of adverse reactions. Additionally, the ability to monitor physiological functions in real-time through functional imaging could lead to more dynamic diagnostic procedures, such as assessing the effectiveness of interventions or treatments in real-time. 3. Financial Impact • Higher Initial Investment: PCCT systems are more expensive than traditional CT scanners due to their advanced technology, which includes photon-counting detectors and the computational power required for high-resolution, molecular, and functional imaging. While this upfront cost is significant, it is crucial to view it in the broader context of the downstream benefits and cost reductions that PCCT offers. • Downstream Cost Reductions: Although the initial capital investment is higher, PCCT’s ability to combine molecular, functional, and ultra-high resolution imaging leads to substantial reductions in downstream healthcare costs. Its superior diagnostic accuracy minimizes the need for follow-up tests, repeat scans, or invasive diagnostic procedures, such as diagnostic coronary angiographies. For example, in cardiology, PCCT can precisely differentiate between types of coronary plaque, reducing the need for invasive procedures to assess risk. • Lower Overall Healthcare Expenditures: By enabling earlier, more accurate diagnoses, PCCT can reduce the overall cost of patient care. Early detection of disease, particularly through its molecular and functional imaging capabilities, allows for more targeted treatments, potentially preventing the need for more aggressive and expensive interventions down the line. For instance, early-stage tumor detection via molecular imaging could lead to less invasive treatments, reducing hospital stays and improving patient outcomes, ultimately driving down healthcare costs. • Increased ROI Through Enhanced Patient Outcomes: Over time, the combination of molecular, functional, and ultra-high resolution imaging enhances diagnostic precision, which translates into better patient outcomes. Improved diagnostic accuracy reduces the incidence of unnecessary procedures, minimizes treatment delays, and results in more personalized and effective care. This leads to increased patient satisfaction, better healthcare outcomes, and greater patient throughput—all factors that improve the institution’s return on investment (ROI). • Competitive Advantage and New Revenue Streams: By adopting PCCT, healthcare institutions position themselves at the forefront of advanced imaging technologies. The ability to offer molecular, functional, and ultra-high resolution imaging creates a competitive advantage, attracting more complex and high-value cases. This can boost the institution’s reputation for excellence in diagnostics, leading to increased referrals, new patient populations, and expanded revenue opportunities. Summary Photon Counting CT (PCCT) is not just an evolution of existing CT technology—it is a molecular, ultra-high resolution, and functional imaging modality that fundamentally transforms the diagnostic landscape. Its ability to capture detailed molecular data, visualize minute anatomical structures with ultra-high resolution, and provide real-time functional imaging opens new possibilities for earlier and more precise diagnoses. While the financial investment in PCCT is larger, the reduction in downstream healthcare costs through improved diagnostic accuracy, fewer unnecessary interventions, and earlier disease detection far outweighs the initial expense. For institutions committed to advancing patient care and improving long-term financial outcomes, PCCT is an essential investment in the future of medical imaging. The video attached shows a patient accessing the Hospital for ACS. PCCT can provide ALL the imaging information of the concurrent imaging modalities (CXR, CAG, Echo, CMR) that you see around it... that's a lot! #PhotonCountingCT #MolecularImaging #UltraHighResolution #FunctionalImaging #FutureOfImaging #AdvancedMedicalImaging #EarlyDiseaseDetection #InnovativeCT #CuttingEdgeHealthcare #PrecisionDiagnostics #HealthcareInnovation #MedicalTechnology #CostEffectiveImaging #NextGenCT #PatientCareRevolution

Dr. Filippo Cademartiri

11,849 views • 1 year ago

𝗘𝘅𝗽𝗹𝗮𝗶𝗻𝗲𝗿: 𝗔𝗻 𝗮𝘁𝘁𝗲𝗺𝗽𝘁 𝗼𝗳 𝗦𝘂𝗸𝗵𝗯𝗶𝗿 𝗦𝗶𝗻𝗴𝗵 𝗕𝗮𝗱𝗮𝗹’𝘀 𝗟𝗶𝗳𝗲 1. 𝗧𝗵𝗲 𝗜𝗻𝗰𝗶𝗱𝗲𝗻𝘁 :- Sukhbir Singh Badal narrowly escaped an assassination attempt at out side of Sri Darbar Sahib (the Golden Temple) while performing Religious Punishment, following a directive from Sri Akal Takht. The attacker, Narayan Singh Chaura, was arrested on the spot. 2. 𝗦𝗲𝗰𝘂𝗿𝗶𝘁𝘆 𝗖𝗼𝗻𝗰𝗲𝗿𝗻𝘀 :- The attempt has raised critical questions: •While the police force successfully prevented the attack, concerns about initial gaps in intelligence and monitoring remain. •The criminal, despite his record, managed to reach a high-security area, indicating potential lapses. 3. 𝗕𝗿𝗼𝗮𝗱𝗲𝗿 𝗜𝗺𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 :- This incident underlines the need for better coordination and vigilance in protecting high-profile figures, especially in sensitive religious spaces. It also adds pressure on law enforcement to reassess and strengthen their protocols. 4. 𝗥𝗲𝗹𝗶𝗴𝗶𝗼𝘂𝘀 𝗣𝘂𝗻𝗶𝘀𝗵𝗺𝗲𝗻𝘁 𝗗𝗲𝗯𝗮𝘁𝗲 :- Days earlier, the Akal Takht issued “Tankhah” (religious punishment) for Akali leaders, including Badal. Some Sikhs believe the punishment was too lenient and divisive. 5. 𝗩𝗶𝗲𝘄 𝗽𝗼𝗶𝗻𝘁 :- Above all, even if someone disagrees with the edict, committing violence is not the answer to stage a protest. #SukhbirBadal #SukhbirBadalAttack

Ravinder Singh Robin

10,438 views • 1 year ago

Today we’re reporting interim Phase 1 clinical data for our REC-617 monotherapy trial – with plans to expand into combination studies in advanced solid tumors. At the AACR Special Conference in Cancer Research, CSO David Hallett shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. 🔹The interim Phase 1 clinical data for REC-617 included: ▫️Dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement; ▫️Confirmed partial response (PR) during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in an advanced setting, with durable response ongoing after more than 6 months of treatment; ▫️In 4 additional patients, a best response of stable disease (SD) for up to 6 months of treatment. Dr. Hallett noted: “Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers. By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index.” "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer. “Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." 👉Learn more: 🔹Join the Update Call: Tomorrow, Tues., Dec. 10 at 8:30am ET, Dr. Hallett and Dr. Khan will hold a live Update Call webcast to present the preliminary data. ▫️Submit questions for the Update Call here: ▫️Tune in to the Update Call here on X or on: LinkedIn: YouTube:

Recursion

11,893 views • 1 year ago

In the crowded subscription app economy, building a great product is no longer enough. As AI has made software significantly faster, easier, and cheaper to build, the primary bottleneck has shifted from product development to distribution. As the serial entrepreneur behind multiple breakout Health & Fitness apps like Fitstar and Zero, Mike Maser has experienced this challenge firsthand. Over the last 15 years, Mike sold his first startup called FitStar to Fitbit, was diagnosed with stage four cancer, made an incredible recovery that he attributes in part to intermittent fasting, and then teamed up with Kevin Rose to build Zero, the world’s #1 fasting app that he has since scaled to $5M+ in ARR and over 10 million registered users. Now, he's navigating Zero through its biggest disruption yet - the rise of GLP-1 medications like Ozempic and Wegovy and the ripple effects they are having on the entire fasting category. Mike breaks down: - Why Zero’s simple one-screen MVP was critical for generating early momentum - How a single tweet from Elon Musk drove $1M in revenue for Zero in 24 hours - Shifting from organic virality to building a sophisticated growth and monetization engine - How Zero adapted its strategy to the GLP-1 era by helping GLP-1 patients track their hydration and manage their protein intake to maintain muscle mass - Zero’s ongoing strategies to reduce subscriber churn and build lifetime subscriber value (0:00) Introduction (2:54) What Zero is and how it created the fasting app category (3:50) Why Mike started building health and fitness apps (10:29) How Mike sold Fitstar while battling stage four cancer (14:57) How intermittent fasting helped Mike beat cancer (18:32) Why Mike took over the Zero app from Kevin Rose (20:53) Why Zero kept its initial app extremely simple (24:53) How Zero's early adopters helped drive initial growth (26:48) How Zero built trust and credibility with early adopters (29:18) How Elon's tweet drove $1M ARR for Zero in one day (32:27) Why GLP-1 medications are reshaping Zero's strategy (36:14) How Zero helps GLP-1 patients protect muscle (42:03) How GLP-1s have expanded Zero's business model (44:41) The loops that will drive Zero's next phase of growth (47:39) Lightning round

In the crowded subscription app economy, building a great product is no longer enough. As AI has made software significantly faster, easier, and cheaper to build, the primary bottleneck has shifted from product development to distribution. As the serial entrepreneur behind multiple breakout Health & Fitness apps like Fitstar and Zero, Mike Maser has experienced this challenge firsthand. Over the last 15 years, Mike sold his first startup called FitStar to Fitbit, was diagnosed with stage four cancer, made an incredible recovery that he attributes in part to intermittent fasting, and then teamed up with Kevin Rose to build Zero, the world’s #1 fasting app that he has since scaled to $5M+ in ARR and over 10 million registered users. Now, he's navigating Zero through its biggest disruption yet - the rise of GLP-1 medications like Ozempic and Wegovy and the ripple effects they are having on the entire fasting category. Mike breaks down: - Why Zero’s simple one-screen MVP was critical for generating early momentum - How a single tweet from Elon Musk drove $1M in revenue for Zero in 24 hours - Shifting from organic virality to building a sophisticated growth and monetization engine - How Zero adapted its strategy to the GLP-1 era by helping GLP-1 patients track their hydration and manage their protein intake to maintain muscle mass - Zero’s ongoing strategies to reduce subscriber churn and build lifetime subscriber value (0:00) Introduction (2:54) What Zero is and how it created the fasting app category (3:50) Why Mike started building health and fitness apps (10:29) How Mike sold Fitstar while battling stage four cancer (14:57) How intermittent fasting helped Mike beat cancer (18:32) Why Mike took over the Zero app from Kevin Rose (20:53) Why Zero kept its initial app extremely simple (24:53) How Zero's early adopters helped drive initial growth (26:48) How Zero built trust and credibility with early adopters (29:18) How Elon's tweet drove $1M ARR for Zero in one day (32:27) Why GLP-1 medications are reshaping Zero's strategy (36:14) How Zero helps GLP-1 patients protect muscle (42:03) How GLP-1s have expanded Zero's business model (44:41) The loops that will drive Zero's next phase of growth (47:39) Lightning round

Phil Carter

16,217 views • 25 days ago

🚨 HMRC just dropped a Call for Evidence on stablecoin taxation TODAY And it could change everything for UK crypto holders 👇 Right now, spending a stablecoin is a CGT event Every transaction. Tracked. Recorded. Calculated. Buy a coffee with USDC? You’re doing a tax computation ☕📊 Pay with your debit card? Nothing. Zero admin. Move on. That is not a level playing field. That is a punishment for using crypto. HMRC have finally acknowledged it 👀 They are now exploring whether stablecoins should be treated like fiat currency for tax purposes Exempt asset status. Removal of reporting thresholds. On the table. This is Stage 1 of the policy process so nothing is law yet But the direction of travel is clear 📍 And I am fully in support Less admin. Fairer rules. More adoption. This is the kind of reform that actually moves the needle for UK crypto 🇬🇧 Link: Go read it yourself. Consultation closes 7 May 2026. Tell me below 👇 are you using stablecoins for payments right now?

🚨 HMRC just dropped a Call for Evidence on stablecoin taxation TODAY And it could change everything for UK crypto holders 👇 Right now, spending a stablecoin is a CGT event Every transaction. Tracked. Recorded. Calculated. Buy a coffee with USDC? You’re doing a tax computation ☕📊 Pay with your debit card? Nothing. Zero admin. Move on. That is not a level playing field. That is a punishment for using crypto. HMRC have finally acknowledged it 👀 They are now exploring whether stablecoins should be treated like fiat currency for tax purposes Exempt asset status. Removal of reporting thresholds. On the table. This is Stage 1 of the policy process so nothing is law yet But the direction of travel is clear 📍 And I am fully in support Less admin. Fairer rules. More adoption. This is the kind of reform that actually moves the needle for UK crypto 🇬🇧 Link: Go read it yourself. Consultation closes 7 May 2026. Tell me below 👇 are you using stablecoins for payments right now?

🇬🇧 Jme 🧪

20,640 views • 6 months ago

Tencent presents GameGen-O Open-world Video Game Generation We introduce GameGen-O, the first diffusion transformer model tailored for the generation of open-world video games. This model facilitates high-quality, open-domain generation by simulating a wide array of game engine features, such as innovative characters, dynamic environments, complex actions, and diverse events. Additionally, it provides interactive controllability, thus allowing for the gameplay simulation. The development of GameGen-O involves a comprehensive data collection and processing effort from scratch. We collect and build the first Open-World Video Game Dataset (OGameData), amassed extensive data from over a hundred of next-generation open-world games, employing a proprietary data pipeline for efficient sorting, scoring, filtering, and decoupled captioning. This robust and extensive OGameData forms the foundation of our model's training process. GameGen-O undergoes a two-stage training process, consisting of foundation model pretraining and instruction tuning. In the first phase, the model is pre-trained on the OGameData via the text-to-video and video continuation, endowing GameGen-O with the capability for open-domain video game generation. In the second phase, the pre-trained model is frozen, and we fine-tuned using a trainable InstructNet, which enables the production of subsequent frames based on multimodal structural instructions. This whole training process imparts the model with the ability to generate and interactively control content. In summary, GameGen-O represents a notable initial step forward in the realm of open-world video game generation via generative models. It underscores the potential of generative models to serve as an alternative to rendering techniques, which can efficiently combine creative generation with interactive capabilities.

Tencent presents GameGen-O Open-world Video Game Generation We introduce GameGen-O, the first diffusion transformer model tailored for the generation of open-world video games. This model facilitates high-quality, open-domain generation by simulating a wide array of game engine features, such as innovative characters, dynamic environments, complex actions, and diverse events. Additionally, it provides interactive controllability, thus allowing for the gameplay simulation. The development of GameGen-O involves a comprehensive data collection and processing effort from scratch. We collect and build the first Open-World Video Game Dataset (OGameData), amassed extensive data from over a hundred of next-generation open-world games, employing a proprietary data pipeline for efficient sorting, scoring, filtering, and decoupled captioning. This robust and extensive OGameData forms the foundation of our model's training process. GameGen-O undergoes a two-stage training process, consisting of foundation model pretraining and instruction tuning. In the first phase, the model is pre-trained on the OGameData via the text-to-video and video continuation, endowing GameGen-O with the capability for open-domain video game generation. In the second phase, the pre-trained model is frozen, and we fine-tuned using a trainable InstructNet, which enables the production of subsequent frames based on multimodal structural instructions. This whole training process imparts the model with the ability to generate and interactively control content. In summary, GameGen-O represents a notable initial step forward in the realm of open-world video game generation via generative models. It underscores the potential of generative models to serve as an alternative to rendering techniques, which can efficiently combine creative generation with interactive capabilities.

AK

367,249 views • 2 years ago

Today San Francisco took its first step to authorize ICE Free Zones at the Board of Supervisors Rules Committee. We've seen what has happened across the country when immigration enforcement occurs at or near public facilities. Kids miss school. Families avoid collecting benefits. Witnesses stop reporting crimes. This ordinance today is about rebuilding trust between residents and city services in 3 ways: 1. Prohibiting the commandeering of city property against city purpose, and explicitly stating civil immigration enforcement is not a city purpose. 2. Setting disciplinary action procedures against employees who collaborate with an external agency to violate city purpose. 3. Authorizing the City Attorney to take action when an entity commandeers city property. I want to thank the many members of the community who helped us craft this legislation, including the SF Public Defender's Office, SF Rising Action Fund , Chinese for Affirmative Action, SF Latino Parity & Equity Coalition, and AROC #FreePalestine #AbolishICE, alongside many labor and community advocates. And I want to thank my coauthor Supervisor Chen, and cosponsors Supervisors Walton, Melgar, Sauter, Fielder, and Mandelman for their support as well. The ordinance now goes to the full Board for a vote tomorrow, and we expect to pass into law in the next month.

Today San Francisco took its first step to authorize ICE Free Zones at the Board of Supervisors Rules Committee. We've seen what has happened across the country when immigration enforcement occurs at or near public facilities. Kids miss school. Families avoid collecting benefits. Witnesses stop reporting crimes. This ordinance today is about rebuilding trust between residents and city services in 3 ways: 1. Prohibiting the commandeering of city property against city purpose, and explicitly stating civil immigration enforcement is not a city purpose. 2. Setting disciplinary action procedures against employees who collaborate with an external agency to violate city purpose. 3. Authorizing the City Attorney to take action when an entity commandeers city property. I want to thank the many members of the community who helped us craft this legislation, including the SF Public Defender's Office, SF Rising Action Fund , Chinese for Affirmative Action, SF Latino Parity & Equity Coalition, and AROC #FreePalestine #AbolishICE, alongside many labor and community advocates. And I want to thank my coauthor Supervisor Chen, and cosponsors Supervisors Walton, Melgar, Sauter, Fielder, and Mandelman for their support as well. The ordinance now goes to the full Board for a vote tomorrow, and we expect to pass into law in the next month.

Bilal Mahmood 馬百樂

35,909 views • 7 months ago